Constructing immunoprofiles to deconstruct disease complexity in pemphigus

Autoimmunity

Volumn 45, Issue 1, 2012, Pages 36-43

  Sinha, Animesh A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antibody; Antigen; Pemphigus; Skin

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; INTERLEUKIN 2; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; DISEASE SEVERITY; FLOW CYTOMETRY; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL PROCEDURES; IMMUNOPHENOTYPING; IMMUNOPROFILING; PEMPHIGUS VULGARIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TH1 CELL;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; PEMPHIGUS; T-LYMPHOCYTES;

EID: 84856504376     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2011.606445     Document Type: Article

References (53)

1. Sinha AA, Brautbar C, Szafer F, Friedmann A, Tzfoni E, Todd JA, Steinman L, McDevitt HO. A newly characterized HLA DQ beta allele associated with pemphigus vulgaris. Science 1988;239:1026-1029. (Pubitemid 18094171)
2. Sinha AA, Lopez MT, McDevitt HO. Autoimmune diseases: The failure of self tolerance. Science 1990;248:1380-1388.
3. Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, Jacob CO, McDermott M, Sinha AA, Timmerman L, Steinman L. A molecular basis for MHC class II-associated autoimmunity. Science 1988;240:1003-1009.
4. Scharf SJ, Friedmann A, Brautbar C, Szafer F, Steinman L, Horn G, Gyllensten U, Erlich HA. HLA class II allelic variation and susceptibility to pemphigus vulgaris. Proc Natl Acad Sci USA 1988;85:3504-3508.
5. Lee E, Lendas KA, Chow S, Pirani Y, Gordon D, Dionisio R, Nguyen D, Spizuoco A, Fotino M, Zhang Y, Sinha AA. Disease relevant HLA class II alleles isolated by genotypic, haplotypic, and sequence analysis in North American Caucasians with pemphigus vulgaris. Hum Immunol 2006; 67:125-139. (Pubitemid 43673911)
6. Arora SK. Analysis of intracellular cytokines using flowcytometry. Meth Cell Sci 2002;24:37-40. (Pubitemid 36826783)
7. Becker BA, Gaspari AA. Pemphigus vulgaris and vegetans. Dermatol Clin 1993;11:429-452. (Pubitemid 23229728)
8. Chow S, Rizzo C, Ravitskiy L, Sinha AA. The role of T cells in cutaneous autoimmune disease. Autoimmunity 2005;38: 303-317. (Pubitemid 40974960)
9. Eming R, Büdinger L, Riechers R, Christensen O, Bohlen H, Kalish R, Hertl M. Frequency analysis of autoreactive T-helper 1 and 2 cells in bullous pemphigoid and pemphigus vulgaris by enzyme-linked immunospot assay. Br J Dermatol 2000;143: 1279-1282. (Pubitemid 32052768)
10. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest 2006;116:1159-1166.
11. Hertl M, Riechers R. Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris. J Dermatol 1999;26:748-752. (Pubitemid 30014422)
12. Rizzo C, Fotino M, Zhang Y, Chow S, Spizuoco A, Sinha AA. Direct characterization of human T cells in pemphigus vulgaris reveals elevated autoantigen-specific Th2 activity in association with active disease. Clin Exp Dermatol 2005;30: 535-540. (Pubitemid 41076023)
13. Veldman C, Pahl A, Beissert S, HansenW, Buer J, Dieckmann D, Schuler G, Hertl M. Inhibition of the transcription factor Foxp3 converts desmoglein 3-specific type 1 regulatory T cells into Th2-like cells. J Immunol 2006;176:3215-3222.
14. Moesta, AK, Rammensee HG, Lin MS, Sinha AA. An HLA class II peptide binding motif-based approach to identify T cell epitopes in pemphigus vulgaris. J Invest Dermatol 2000; 114:846.
15. Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, Bystryn JC, Cianchini G, Diaz L, Fivenson D, Hall R, Harman KE, Hashimoto T, Hertl M, Hunzelmann N, Iranzo P, Joly P, JonkmanMF, Kitajima Y, Korman NJ, Martin LK, Mimouni D, Pandya AG, Payne AS, Rubenstein D, Shimizu H, Sinha AA, Sirois D, Zillikens D, Werth VP. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008;58:1043-1046.
16. + CD25high regulatory T cells are markedly decreased in blood of patients with pemphigus vulgaris. Dermatology 2007;214:210-220. (Pubitemid 46457606)
17. Veldman C, Pahl A, Hertl M. Desmoglein 3-specific T regulatory 1 cells consist of two subpopulations with differential expression of the transcription factor Foxp3. Immunology 2009;127:40-49.
18. + CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 2006; 108:4260-4267. (Pubitemid 44913302)
19. + T cell responses to glutamic acid decarboxylase 65. Eur J Immunol 2007;37:78-86. (Pubitemid 46128788)
20. + regulatory T cells in the maintenance of T cell homeostasis. J Exp Med 2004;200:1123-1134. (Pubitemid 39507052)
21. Arbour N, Lapointe R, Saikali P, McCrea E, Regen T, Antel JP. A new clinically relevant approach to expand myelin specific T cells. J Immunol Meth 2006;310:53-61. (Pubitemid 43375975)
22. Wucherpfennig KW, Yu B, Bhol K, Monos DS, Argyris E, Karr RW, Ahmed AR, Strominger JL. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: Charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci U S A 1995;92: 11935-11939.
23. Lin MS, Swartz SJ, Lopez A, Ding X, Fernandez-Vina MA, Stastny P, Fairley JA, Diaz LA. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J Clin Invest 1997;99:31-40. (Pubitemid 27058291)
24. Veldman C, Stauber A, Wassmuth R, Uter W, Schuler G, Hertl M. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J Immunol 2003;170:635-642. (Pubitemid 36026193)
25. Veldman CM, Gebhard KL, UterW,Wassmuth R, Grotzinger J, Schultz E, Hertl M. T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. J Immunol 2004;172:3883-3892. (Pubitemid 38337976)
26. Baroni A, Perfetto B, Ruocco E, Greco R, Criscuolo D, Ruocco V. Cytokine pattern in blister fluid and sera of patients with pemphigus. Dermatology 2002;205:116-121.
27. Ludwig RJ, Schmidt E. Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis? G Ital Dermatol Venereol 2009;144:339-349.
28. Satyam A, Khandpur S, Sharma VK, Sharma A. Involvement of T(H)1/T(H)2 cytokines in the pathogenesis of autoimmune skin disease-Pemphigus vulgaris. Immunol Invest 2009;38: 498-509.
29. Opreanu CR, Seiffert K, Sinha AA. Multiplexed array analysis supports disease phase related cytokine profiles in pemphigus vulgaris. J Invest Dermatol 2008;128:86.
30. Fiorentino DF, Garcia MS, Rehmus W, Kimball AB. A pilot study of etanercept treatment for pemphigus vulgaris. Arch Dermatol 2011;147:117-118.
31. Shetty A, Marcum CB, Glass LF, Carter JD. Successful treatment of pemphigus vulgaris with etanercept in four patients. J Drugs Dermatol 2009;8:940-943.
32. Arakawa M, Dainichi T, Yasumoto S, Hashimoto T. Lesional Th17 cells in pemphigus vulgaris and pemphigus foliaceus. J Dermatol Sci 2009;53:228-231.
33. Toto P, Feliciani C, Amerio P, Suzuki H, Wang B, Shivji GM, Woodley D, Sauder DN. Immune modulation in pemphigus vulgaris: Role of CD28 and IL-10. J Immunol 2000;164: 522-529. (Pubitemid 30013029)
34. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991;67:869-877. (Pubitemid 121001501)
35. Mahoney MG,Wang ZH, Stanley JR. Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice. J Invest Dermatol 1999;113:22-25. (Pubitemid 29328153)
36. Kalish RS. Pemphigus vulgaris: The other half of the story. J Clin Invest 2000;106:1433-1435. (Pubitemid 32038579)
37. Kalantari-Dehaghi M, Molina DM, Farhadieh M, Morrow WJ, Liang X, Felgner PL, Grando SA. New targets of pemphigus vulgaris antibodies identified by protein array technology. Exp Dermatol 2011;20:154-156.
38. Patel M, Furstenberg G, Hazelton J, Tiagi S, Seiffert-Sinha K, Haab BB, Robinson WH, Sinha AA. Development of protein microarrays to investigate autoantibody profiles in pemphigus vulgaris. J Invest Dermatol 2010;130:S19 (abstract 549).
39. Talsma J, Stepanovich M, Chow S, Seiffert K, Sinha AA. Dichotomy of anti-desmoglein 1 and -3 autoantibody profiles in pemphigus vulgaris patients carrying distinct HLA alleles. J Invest Dermatol 2007;127:16.
40. Dhandha M, Seiffert-Sinha K, Sinha AA. Specific immunoglobulin isotypes correlate with disease activity, morphology, duration, and HLA association in Pemphigus vulgaris (PV). J Invest Dermatol 2009;129:14.
41. Ayatollahi M, Joubeh S, Mortazavi H, Jefferis R, Ghaderi A. IgG4 as the predominant autoantibody in sera from patients with active state of pemphigus vulgaris. J Eur Acad Dermatol Venereol 2004;18:241-242. (Pubitemid 38379924)
42. Bhol K, Mohimen A, Ahmed AR. Correlation of subclasses of IgG with disease activity in pemphigus vulgaris. Dermatology 1994;189(Suppl 1):85-89. (Pubitemid 24141436)
43. Kricheli D, David M, Frusic-Zlotkin M, Goldsmith D, RabinovM, Sulkes J, Milner Y. The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in pemphigus patients and their first-degree relatives. Br J Dermatol 2000;143:337-342. (Pubitemid 30650402)
44. Nagel A, Lang A, Engel D, Podstawa E, Hunzelmann M, de Pita O, Borradori L, Uter W, Hertl M. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clin Immunol 2010;134:320-330.
45. Spaeth S, Riechers R, Borradori L, Zillikens D, Büdinger L, Hertl M. IgG, IgA and IgE autoantibodies against the ectodomain of desmoglein 3 in active pemphigus vulgaris. Br J Dermatol 2001;144:1183-1188. (Pubitemid 34204209)
46. Amagai M. Pemphigus vulgaris and its active disease mouse model. Curr Dir Autoimmun 2008;10:167-181.
47. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982;306: 1189-1196. (Pubitemid 12158848)
48. Cirillo N, Gombos F, Lanza A. Pemphigus vulgaris immunoglobulin G can recognize a 130-000MW antigen other than desmoglein 3 on peripheral blood mononuclear cell surface. Immunology 2007;121:377-382. (Pubitemid 46817359)
49. Evangelista F, Dasher DA, Diaz LA, Prisayanh PS, Li N. Ecadherin is an additional immunological target for pemphigus autoantibodies. J Invest Dermatol 2008;128:1710-1718. (Pubitemid 351847386)
50. Kurzen H, Brenner S. Significance of autoimmunity to nondesmoglein targets in pemphigus. Autoimmunity 2006;39: 549-556. (Pubitemid 44768923)
51. Nguyen VT, Ndoye A, Shultz LD, Pittelkow MR, Grando SA. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions. J Clin Invest 2000;106:1467-1479. (Pubitemid 32038585)
52. Patel M, Furstenberg G, Hazelton J, Tiagi S, Seiffert-Sinha K, Haab BB, Robinson WH, Sinha AA. Development of protein microarrays to investigate autoantibody profiles in pemphigus vulgaris. J Invest Dermatol 2010;130:S19.
53. Grando SA. Autoimmunity to keratinocyte acetylcholine receptors in pemphigus. Dermatology 2000;201:290-295. (Pubitemid 32037553)